Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study-Reference-Cited by-同舟云学术

Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study

Published:2015-04 Issue:4 Volume:2 Page:317-323
ISSN:2352-3964
Container-title:EBioMedicine
language:en
Short-container-title:EBioMedicine

Author:

Yoshino Takayuki,Muro Kei,Yamaguchi Kensei,Nishina Tomohiro,Denda Tadamichi,Kudo Toshihiro,Okamoto Wataru,Taniguchi Hiroya,Akagi Kiwamu,Kajiwara Takeshi,Hironaka Shuichi,Satoh Taroh

Funder

Medical & Biological Laboratories Co., Ltd

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Reference28 articles.

1. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J. Clin. Oncol.,2008

2. KRAS mutations detected by the amplification refractory mutation system-Scorpion assays strongly correlate with therapeutic effect of cetuximab;Bando;Br. J. Cancer,2011

3. Simultaneous identification of 36 mutations in KRAS codons 61and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit;Bando;BMC Cancer,2013

4. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer;Bokemeyer;J. Clin. Oncol.,2009

5. Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples;Didelot;Exp. Mol. Pathol.,2012

Cited by 55 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development and Validation of a Multi-marker Liquid Bead Array Assay for the simultaneous detection of PIK3CA and ESR1 hotspot mutations in single circulating tumor cells (CTCs);Heliyon;2024-09

2. Mul'tipleksnaia tekhnologiia xMAP;Fundamental and applied research for key propriety areas of bioecology and biotechnology;2024-06-05

3. Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer;Nature Medicine;2024-02-12

4. RAS mutation status in combination with the JSHBPS nomogram may be useful for preoperative identification of colorectal liver metastases with high risk of recurrence and mortality after hepatectomy;Journal of Hepato-Biliary-Pancreatic Sciences;2023-10-27

5. Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer;JAMA;2023-04-18